Characteristics of study participants
| Cohort . | N . | Age* (range) . | Diagnosis . | Conditioning . | Donor . | GVHD . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AML . | ALL . | MA . | RIC . | MUD . | Sib . | Acute . | Chronic . | |||
| 1 | 11 | 50 (19-70) | 9† | 2 | 0 | 6 | 4 | 2 | 1 | 3 |
| 2 | 12 | 43 (25-65) | 12 | 0 | 3 | 9 | 12 | 0 | — | — |
| 28 | 51 (15-65) | 28 | 0 | 19 | 9 | 14 | 14 | 24 | 22 | |
| Cohort . | N . | Age* (range) . | Diagnosis . | Conditioning . | Donor . | GVHD . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AML . | ALL . | MA . | RIC . | MUD . | Sib . | Acute . | Chronic . | |||
| 1 | 11 | 50 (19-70) | 9† | 2 | 0 | 6 | 4 | 2 | 1 | 3 |
| 2 | 12 | 43 (25-65) | 12 | 0 | 3 | 9 | 12 | 0 | — | — |
| 28 | 51 (15-65) | 28 | 0 | 19 | 9 | 14 | 14 | 24 | 22 | |
MA, myeloablative conditioning (busulfan, cyclophosphamide ± ATG); MUD, matched-unrelated donor; RIC, reduced-intensity conditioning (cohort 1: fludarabine, total body irradiation ± ATG; cohort 2: fludarabine, busulfan ± ATG); Sib, sibling donor.
Median age in years.
Five patients in cohort 1 did not proceed to HSCT and were therefore studied during the induction phase only.